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AbsTrACT
background Fabry disease is a treatable X-linked 
condition leading to progressive cardiomyopathy, 
arrhythmia and premature death. atrial and ventricular 
arrhythmias contribute significantly to adverse prognosis; 
however, guidance to determine which patients require 
cardiovascular implantable electronic devices (cieDs) is 
sparse. We aimed to evaluate indications for implantation 
practice in the UK and quantify device utilisation.
Methods in this retrospective study, we included 
demographic, clinical and imaging data from patients 
in four of the largest UK Fabry centres. ninety patients 
with Fabry disease were identified with cieDs implanted 
between June 2001 and February 2018 (FD-cieD group). 
to investigate differences in clinical and imaging markers 
between those with and without devices, these patients 
were compared with 276 patients without a cieD (FD-
control).
results in the FD-cieD group, 92% of patients with 
permanent pacemakers but only 28% with implantable 
cardioverter-defibrillators had a class 1 indication for 
implantation. a further 44% of patients had defibrillators 
inserted for primary prevention outside of current 
guidance. the burden of arrhythmia requiring treatment 
in the FD-cieD group was high (asymptomatic atrial 
fibrillation:
29%; non-sustained ventricular tachycardia requiring 
medical therapy alone: 26%; sustained ventricular 
tachycardia needing anti-tachycardia pacing/
defibrillation: 28%). those with devices were older, had 
greater lV mass, more scar tissue and larger atrial size.
Conclusions arrhythmias are common in Fabry 
patients. those with cardiac devices had high rates of 
atrial fibrillation requiring anticoagulation and ventricular 
arrhythmia needing device treatment. these are as high 
as those in hypertrophic cardiomyopathy, supporting 
the need for Fabry-specific indications for device 
implantation.
InTroduCTIon
Fabry disease (FD) is an X-linked lysosomal storage 
disorder caused by a deficiency in the enzyme 
α-Galactosidase A,1 which leads to progressive 
accumulation of sphingolipids.2 This leads to 
cellular dysfunction and life-threatening cardio-
vascular, renal and neurological complications.3 
The advent of enzyme replacement (ERT) and oral 
chaperone therapy has altered the natural history 
of FD, with cardiovascular disease now the main 
cause of morbidity and mortality.4 Cardiac involve-
ment includes progressive left ventricular hyper-
trophy (LVH), myocardial inflammation, fibrosis, 
arrhythmia, congestive cardiac failure and sudden 
death.5 Sphingolipids accumulate in all cardiac cells 
including the conduction system.6 This triggers a 
cascade of cellular reactions leading to a proinflam-
matory microenvironment with local tissue injury 
and apoptosis.7 The ensuing damage to conductive 
tissue contributes to electrical instability and subse-
quent development of arrhythmia. Although symp-
toms such as palpitations and syncope are common 
in FD, little is known regarding the true frequency 
of arrhythmia.4 Registry data and small single centre 
studies suggest that the rate of atrial arrhythmias 
such as atrial fibrillation (AF) could be as high as 
13%,8 while the reported incidence of ventricular 
arrhythmia varies widely from 5% to 30%,9–11 with 
a progressive increase with advancing age.12
A number of clinical and imaging parame-
ters have been identified as markers of poten-
tial arrhythmia,13 14 but no criteria exist to guide 
implantation of cardiovascular implantable elec-
tronic devices (CIEDs) for primary prevention. 
Furthermore, FD is specifically excluded from the 
risk prediction tool for sudden cardiac death used 
in hypertrophic cardiomyopathy (HCM),15 despite 
similarities in risk factors between FD and HCM.16 
Data are lacking on the reasons for implantation of 
CIEDs in FD and on device utilisation following 
implantation.17 18
The aims of our study were to evaluate the 
indications for CIEDs applied in clinical practice, 
to quantify arrhythmia burden and device usage 
in patients with FD and to investigate differences 
in clinical characteristics between those with and 
without a device.
MeThods
study population
This study conformed to the principles of Good 
Clinical Practice guidelines. The study consisted of 
patients with genetically confirmed FD followed up 
at national specialist centres within the UK: Queen 
Elizabeth Hospital, Birmingham; Salford Royal 
Hospital, Salford; Royal Free Hospital, London; 
and Addenbrookes Hospital, Cambridge. We 
included all patients who had a therapeutic CIED, 
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Table 1 All arrhythmic events and criteria required for classification
Arrhythmia type Criteria
Atrial fibrillation Episode >30 s in duration.
Non-sustained VT Three or more ventricular beats at a rate 
>120 bpm for a duration of <30 s.
Sustained VT Ventricular tachycardia for a duration of 
>30 s.
VT with haemodynamic compromise Sustained VT with haemodynamic instability, 
for example, hypotension or syncope.
VT, ventricular tachycardia; bpm, beats per minute.
including a permanent pacemaker (PPM), implantable cardio-
verter-defibrillator (ICD) or cardiac resynchronisation therapy 
(CRT), implanted between 1 June 2001 and 1 February 2018 
(FD-CIED group). The clinical notes of all patients both current 
and historical under follow-up within each centre were manu-
ally reviewed to identify whether a cardiac device had been 
implanted and to define the study cohort. A comparator group 
included patients recruited to the Fabry400 study ( ClinicalTrials. 
gov: NCT03199001), which is a separate observational study 
evaluating the role of cardiovascular magnetic resonance (CMR) 
imaging in FD.19
baseline assessment
Baseline FD specific information included genetic muta-
tion (classical or non-classical variant), other FD-target organ 
involvement and the Mainz Severity Score Index (MSSI).20 
The presence of ischaemic heart disease (IHD) was defined as 
evidence of a flow-limiting lesion on coronary angiography 
requiring treatment (surgical, percutaneous or medical). In the 
FD-CIED group, cardiac investigations were recorded if these 
had been performed before or within 3 months following device 
implantation. These included transthoracic echocardiography, 
CMR imaging and a 12-lead electrocardiogram (ECG), which 
were performed in accordance with standardised protocols. In 
the FD-control cohort, the most recent investigations during the 
Fabry400 study period were captured through clinical record 
analysis. Classification of an ECG as abnormal included the pres-
ence of the following: prolonged or shortened PR interval, QRS 
duration >120 ms, minor conduction disturbances (intraventric-
ular conduction abnormalities and bundle branch block patterns 
<120 ms), the presence of LVH by Sokolow-Lyon criteria, T 
wave inversion in at least two contiguous leads and the presence 
of multifocal ventricular ectopy. LVH was defined as a maximum 
wall thickness greater than 12 mm, and left atrial dilatation was 
classified as a biplanar volume indexed to body surface area 
greater than 28 mL/m2.21
Follow-up
CIED follow-up reports were obtained from the date of 
device implantation until the study end date. If diagnosis of an 
arrhythmia was unclear from clinical notes, device electrocar-
diograms were reviewed. Details of changes in treatment were 
obtained from clinical notes. Table 1 describes the diagnostic 
criteria for arrhythmic events.
statistical analysis
Statistical analyses were carried out using SPSS V.23. All contin-
uous variables are expressed as mean±SD, and all non-con-
tinuous data are expressed as frequencies or percentages. 
Normality was evaluated using the Shapiro-Wilk test. Groups 
were compared with independent t-testing for parametric data 
and Mann-Whitney U testing for non-parametric data. χ2 or 
Fisher’s exact testing was used to compare proportions within 
two independent groups. Comparisons between multiple groups 
were performed using analysis of variance testing with post hoc 
Tukey correction. Time-to-event analysis was performed to eval-
uate the presence of arrhythmic events. Kaplan-Meier curves 
were used to show time to first new diagnosis of AF, ventric-
ular arrhythmia and first appropriate ICD therapy, whereas a 
multivariable Cox model was used for the occurrence of any 
arrhythmia requiring treatment during follow-up (online supple-
mentary table 1). Proportionality of hazards was assessed by 
visual inspection of Kaplan-Meier curves for each predictor vari-
able. A p value of <0.05 was considered statistically significant.
resulTs
study cohort characteristics
Of the UK population of 880 Fabry patients in the four national 
centres, 90 (10%) had a therapeutic cardiac device implanted 
between 1 June 2001 and 1 February 2018. The FD-CIED group 
had a median follow-up of 4.3 years (IQR 2.2–7.7 years). These 
patients are compared with detailed cardiac data from 276 Fabry 
patients without a device in the FD-control group. Baseline char-
acteristics are described in table 2. The FD-CIED cohort was 
older, more often male and more frequently had a non-classical 
mutation (predominantly with a cardiac variant, N215S protein 
sequence change). Furthermore, disease severity was more 
advanced in the FD-CIED patients, reflected by higher mean 
MSSI score, increased prevalence of LVH, ECG abnormalities 
and late gadolinium enhancement (LGE) on CMR (see table 2). 
Eighteen patients (20%) in the FD-CIED group had chronic 
kidney disease stage 3 or above, with two of these patients 
having undergone renal transplantation, compared with two 
patients (0.7%) in the controls. Sixty-two patients (69%) were 
on ERT at time of device implantation, and this was the case in 
only 131 of the control patients (47%). Baseline Holter moni-
toring was performed in 52/90 patients (58%) in the FD-CIED 
group and 37 of these (71%) were abnormal leading to initia-
tion of medical therapy or device implantation (non-sustained 
ventricular tachycardia (NSVT): 22/52, 42%; SVT: 6/52, 12%; 
atrioventricular (AV) conduction abnormality: 9/52, 17%). Of 
note, 19 patients underwent implantation of diagnostic implant-
able loop recorder (ILR) devices and complete data can be seen 
in online supplementary table 2.
Cardiac device implantation (Fd-CIed group)
The following devices were implanted: PPMs for bradycardia: 
38/90 (42%), ICDs for tachyarrhythmia: 43/90 (48%) and CRT 
for heart failure: 9/90 (10%). Indications for CIED implantation 
can be seen in table 3. Of those with PPMs, 79% had a class 1 
indication for device implantation and 13% a class 2a indication, 
according to European Society of Cardiology guidance.17 The 
indications for ICD implantation were more variable with only 
28% having a class 1 indication for CIED insertion.18 Forty-four 
per cent of patients underwent ICD implantation for primary 
prevention outside of national guidance (persisting heart failure 
symptoms with a left ventricular ejection fraction <35% despite 
optimal medical therapy for 3 months22) but based on clinical 
suspicion of arrhythmia (severe LVH, extensive LGE, abnormal 
resting ECG, previous NSVT on ECG monitoring or a family 
history of sudden cardiac death). In all cases, the decision to 
implant a device followed discussion within an electrophysiology 
multidisciplinary team meeting. In 26 patients (29%), device 
implantation preceded a diagnosis of FD. Subgroup analysis of 
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Table 2 Baseline demographic and investigation data: FD-CIED 
versus FD-control
Fd-CIed Fd-control P value*
Sample size (n) 90 276 N/A
Age (years) 56±13 46±16 <0.001
Male gender (n, %) 69 (76.7) 100 (36.2) <0.001
On ERT (n, %) 62 (68.9) 131 (47.5) <0.001
Classical mutation (n, %) 39 (43) 163 (59) 0.010
BMI (kg/m2) 27±6 25±5 0.002
HR (bpm) 71±18 65±13 0.064
SBP (mm Hg) 125±18 123±18 0.406
DBP (mm Hg) 74±11 74±10 0.914
MSSI 15.1±9.7 7.3±7.7 <0.001
Comorbidities       
  IHD (n, %) 6 (6.7) 7 (2.5) 0.115
  CKD stage 3–5 (n, %) 18 (20) 26 (9.4) 0.017
  eGFR (median, IQR) 82 (46 to 74) 84 (72–90) 0.017
  HTN (n, %) 18 (20) 35 (12.7) 0.120
  DM (n, %) 8 (8.9) 8 (2.9) 0.046
  Stroke/TIA (n, %) 22 (24.4) 11 (4.0) <0.001
ECG n=76 n=239   
  Abnormal (n, %) 74 (97.4) 115 (48.1) <0.001
  AF/PAF (n, %) 8 (10.5) 9 (3.7) 0.037
  PR interval (ms) 174±40 147±28 <0.001
  QRS duration (ms) 136±32 99±20 <0.001
Holter monitoring n=52 n=85   
  Abnormal 37 (71.2) 12 (14.1) <0.001
Echocardiography n=82 n=91   
  LVEF (%) 57±13 62±7 0.002
  LVH (n, %) 78 (95.1) 36 (39.6) <0.001
  LA dilatation (n, %) 56 (68.3) 13 (14.3) <0.001
CMR n=46 n=210   
  LVMi (g/m2) 150±37.3 83±36 <0.001
  MWT (mm) 20±4.9 12±4.6 <0.001
  LVEDVi (mL/m2) 82±32 70±14 0.143
  LVESVi (mL/m2) 31±31 19±7 0.150
  LGE (n, %) 29 (63.0) 85 (40.5) <0.05
*P-values are comparing FD-CIED versus FD-control.
AF, atrial fibrillation; BMI, body mass index; CKD, chronic kidney disease; CMR, 
cardiac magnetic resonance; DBP, diastolic blood pressure; DM, diabetes mellitus; 
ECG, electrocardiogram; ERT, enzyme replacement therapy; FD-CIED, Fabry 
disease with cardiovascular implantable electronic device; HR, heart rate; HTN, 
hypertension; IHD, ischemic heart disease; LA, left atrium; LGE, late gadolinium 
enhancement; LVEDVi, indexed left ventricular end-diastolic volume; LVEF, left 
ventricular ejection fraction; LVESVi, indexed left ventricular end-systolic volume; 
LVH, left ventricular hypertrophy; LVMi, indexed left ventricular mass; MSSI, Mainz 
Severity Score Index; MWT, maximum wall thickness; PAF, paroxysmal atrial 
fibrillation; SBP, systolic blood pressure; TIA, transient ischemic attack; eGFR, 
estimated glomerular filtration rate.
Table 3 Indications for CIED insertion
CIed indication Frequency Percentage (%)
PPM (n=38)
  Tachy-brady with coexisting AF 5 13.2
  Sinus node dysfunction 9 23.7
  Bifascicular and trifascicular block 3 7.9
  Second degree AV block 10 26.2
  Third degree AV block 9 23.7
  No clear indication 2 5.3
ICD (n=43)
  Presumed dual pathology with HCM 7
(three confirmed 
mutation)
16.3 (7.0)
  Symptomatic VT 9 20.9
  Multiple risk factors 14 32.6
  PPM indication with asymptomatic 
NSVT
4 9.3
  Asymptomatic NSVT 8 18.6
  Other (LQTS with syncope) 1 2.3
CRT (n=9)
  Symptomatic LVSD (NYHA class 3) with 
LBBB
7 77.8
  No clear indication 2 22.2
AF, atrial fibrillation; AV, atrioventricular; CIED, cardiovascular implantable electronic 
device; CRT, cardiac resynchronisation therapy; HCM, hypertrophic cardiomyopathy; 
ICD, implantable cardioverter-defibrillator; LBBB, left bundle branch block; LQTS, 
long QT syndrome; LVSD, left ventricular systolic dysfunction; NSVT, non-sustained 
ventricular tachycardia; NYHA, New York Heart Association; PPM, permanent 
pacemaker; VT, ventricular tachycardia.
Figure 1 Arrhythmic events per year in the FD cohort with cardiac 
devices. AF, atrial fibrillation; ATP, antitachycardia pacing; NSVT, non-
sustained ventricular tachycardia; SVT, supraventricular tachycardia; VT, 
ventricular tachycardia.
device type showed no differences in baseline demographic data 
and therefore all therapeutic CIEDs were evaluated as a single 
cohort (online supplementary table 3).
Follow-up and baseline clinical characteristics
Arrhythmia follow-up: FD-CIED group
A total of 58/90 patients (64%) in the FD-CIED group had at 
least one documented arrhythmia. Forty of these (44%) required 
initiation of or a change in therapy: 17/58 (29%) were diag-
nosed with new AF requiring anticoagulation and rate control 
medication, 4/58 (6.9%) had supraventricular tachycardia 
(SVT) requiring beta-blocker therapy and 15/58 (26%) had 
NSVT requiring medical therapy (beta-blocker or amiodarone). 
Figure 1 demonstrates the incidence of arrhythmic events per 
year of follow-up. The number of total arrhythmic events per 
100 patient years in the FD-CIED group followed a similar trend 
(table 4).
Decision to commence medical therapy for NSVT and subse-
quent dose titration was variable depending on follow-up 
centre, frequency of NSVT and the presence of other potential 
arrhythmic risk factors. Not all patients started on treatment for 
NSVT were symptomatic. Twenty-five out of 90 (28%) of the 
FD-CIED cohort had short episodes of asymptomatic NSVT 
(3–5 beats) during follow-up that were not treated. Time to 
first atrial and ventricular arrhythmia in the FD-CIED group is 
shown in figure 2A, B. Of the 17 patients who had AF diag-
nosed on CIED follow-up, three strokes were recorded prior 
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Table 4 Arrhythmic events in the FD-CIED cohort
number of patients 
with at least one 
event
events per 100 
patient years
All documented arrhythmia 58/90 15.0
Arrhythmia needing treatment 40/90 10.3
AF needing anticoagulation 17/58 6.8
NSVT 15/58 6.0
VT needing ATP and/or defibrillation 14/50 7.6
VT needing defibrillation 8/50 4.3
AF, atrial fibrillation; ATP, antitachycardia pacing; FD-CIED, Fabry disease with a 
cardiovascular implantable electronic device; NSVT, non-sustained ventricular 
tachycardia; VT, ventricular tachycardia.
Figure 2 Kaplan-Meier curves illustrating cumulative event rate of atrial and ventricular arrhythmia and cumulative time to first appropriate ICD 
therapy in the FD cohort with cardiac devices. Panel A: time to first new diagnosis of AF. Panel B: time to first episode of ventricular arrhythmia. 
Panel C: time to first appropriate ICD therapy (ATP/defibrillation). These Kaplan-Meier curves do not relate to mortality and only the occurrence of an 
arrhythmic event. AF, atrial fibrillation; ATP, antitachycardia pacing; ICD, implantable cardioverter-defibrillator.
to anticoagulation, and no further episodes were documented 
after treatment. There were no differences in the incidence of 
arrhythmia needing therapy between those on ERT compared 
with those not on any disease-modifying therapy (online supple-
mentary figure 1). Of the six FD-CIED patients with flow-lim-
iting IHD, two were found to have an arrhythmia requiring 
medical treatment—one with NSVT and another with a short 
burst of AF (both less than 30 s in duration). There were 11 
deaths during follow-up: two patients died following sustained 
ventricular arrhythmia, one patient with end-stage heart failure 
and the remainder died of non-cardiac causes.
From the FD-CIED cohort, 50 had defibrillator capability 
within their cardiac device (43 with an ICD and 7 with a cardiac 
resynchronisation therapy defibrillator (CRT-D). Sustained 
ventricular tachycardia (VT) needing anti-tachycardia pacing 
(ATP) or defibrillation occurred in 28% of patients (14/50) over 
a median follow-up duration of 3.7 years (IQR 1.8–6.2 years). 
VT with haemodynamic compromise needing defibrillation 
occurred in 16% of FD-CIED patients (8/50). Figure 2C shows 
a Kaplan-Meier curve for the occurrence of an arrhythmic event 
needing ICD therapies (ATP and defibrillation) in this cohort. 
Inappropriate defibrillation occurred in 2/50 patients (4%), both 
of whom subsequently underwent lead repositioning. When 
comparing those who had class 1 indications for ICD insertion 
to those who had a device implanted for primary prevention 
outside of guidelines, there were no differences in the occurrence 
of all arrhythmia types (any arrhythmia requiring therapy: 
6/12 vs 8/19, p=0.410; VT with haemodynamic compromise 
requiring defibrillation: 3/12 vs 0/19, p=0.087; AF: 2/12 vs 
2/19, p=0.277).
Arrhythmia follow-up: FD-control group
Of the FD-control cohort, 85/276 (31%) underwent Holter 
monitoring during the study period, with 12 of these identi-
fying abnormalities. An alteration in therapy was required in 
10/85 patients (12%): NSVT: four requiring medication and one 
currently under consideration for ICD implantation; SVT: four 
requiring anticoagulation/beta blockade for AF and one medical 
treatment for AV nodal re-entrant tachycardia). There were four 
deaths during follow-up: one sudden cardiac death suspected to 
be arrhythmic in nature and the remaining three from non-car-
diac causes.
Clinical characteristics: FD-CIED versus FD-control
Patients with a cardiac device were older and more often male 
compared with those in the control cohort (table 2). There were 
also differences in electrical and structural parameters on base-
line cardiac investigations, with the FD-CIED group having 
a longer PR interval and QRS duration, a greater LV mass, 
more scar tissue and more frequent LA dilatation. The distri-
bution of baseline characteristics in different event categories 
(NSVT, AF and sustained VT/VF needing defibrillation) can be 
seen in table 5. There were no differences in clinical, ECG or 
imaging parameters between FD-CIED patients with arrhythmia 
requiring therapy (NSVT, AF and sustained VT/VF) compared 
with those who did not have arrhythmia. In the FD-control 
cohort, however, there was a tendency towards a higher LV 
mass, dilated left atrium, prolonged PR interval and QRS dura-
tion and an elevated MSSI in those who had an arrhythmia 
requiring treatment, but this did not reach statistical significance 
as we believe the number of events was low. Analysis using Cox 
regression showed no significant predictors for the presence of 
any arrhythmia requiring treatment (online Supplementary Table 
1). In addition to the eight patients who had haemodynamically 
significant VT needing defibrillation, one further patient with a 
PPM died from sustained VT and VF identified from postmortem 
device interrogation. Of these nine patients with symptomatic 
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Table 5 Distribution of baseline characteristics according to outcome: treated arrhythmia versus no arrhythmia
Fd-CIed Fd-control
A. NSVT
No NSVT (n=49) NSVT (n=41) P value No NSVT (n=221) NSVT (n=5) P value
LVH (n, %) 41 (83.7) 37 (90.2) 0.353 32/86 (37.2) 4/5 (80) 0.078
LGE* (n, %) 14/21 (66.7) 15/19 (78.9) 0.648 83/207 (40.1) 2/3 (66.7) 0.567
LA dilatation* (n, %) 28 (57.1) 28 (68.3) 0.815 12/57 (21.1) 1/4 (25) NS
PR interval (ms) 186±42 163±36 0.020 145±28 157±35 0.455
QRS duration (ms) 138±34 133±30 0.520 99±20 118±32 0.257
MSSI 15.4±10.6 14.7±8.5 0.742 6.6±6.9 16.6±12.3 0.013
B. AF
  No AF (n=73) AF (n=17) P value No AF (n=222) AF (n=4) P value
LVH (n, %) 61 (83.5) 17 (100) 0.575 32/87 (36.8) 4/4 (100) 0.022
LGE* (n, %) 19/29 (65.5) 10/11 (90.9) 0.033 84/207 (40.6) 1/3 (33.3) NS
LA dilatation* (n, %) 43 (58.9) 13 (76.4) 0.562 11/5819 2/3 (66.7) 0.112
PR interval (ms) 172±39 182±46 0.440 147±27 218 0.011
QRS duration (ms) 135±33 139±30 0.686 99±20 123±12 0.041
MSSI 15.4±10.4 13.7±5.9 0.504 7.1±7.7 12±7.2 0.110
C. VT with haemodynamic compromise or VF needing defibrillation
  No ICD shock (n=82) ICD shock (n=8) P value
LVH (n, %) 72 (87.8) 6 (75) 0.046
LGE* (n, %) 26/37 (70.2) 3/3 (100) 0.542
LA dilatation* (n, %) 52 (63.4) 4 (50) 0.256
PR interval (ms) 175±41 166±37 0.526
QRS duration (ms) 138±32 113±18 0.071
MSSI 15.2±9.3 13.1±13.9 0.586
The presence of specific clinical characteristics was evaluated in those with a treated arrhythmia in the FD-CIED and FD-control cohorts: NSVT (table 5a), AF (table 5b) and VT 
requiring defibrillation (table 5c, FD-CIED group only). Arrhythmia data were collected from CIED follow-up in the FD-CIED group and from Holter monitor testing in the FD-
control group.
*Not all underwent CMR or transthoracic echocardiography imaging.
AF, atrial fibrillation; CMR, cardiovascular magnetic resonance; FD-CIED, Fabry disease with a cardiovascular implantable electronic device; ICD, implantable cardioverter 
defibrillator; LA, left atrium; LGE, late gadolinium enhancement; LVH, left ventricular hypertrophy; MSSI, Mainz Severity Score Index; NS, non-significant; NSVT, non-sustained 
ventricular tachycardia; VF, ventricular fibrillation; VT, ventricular tachycardia.
VT, seven shared the following clinical characteristics: male 
>40 years, severe LVH, extensive LGE and an abnormal ECG 
with a QRS duration >120 ms. The remaining two patients 
included a female with coexisting familial long QT syndrome 
and a history of recurrent sustained VT and a 52 year-old man 
who had an ICD implanted following a short episode of NSVT.
dIsCussIon
This study has shown that device implantation is frequent 
despite a lack of disease-specific guidance in FD.8 23 The burden 
of arrhythmia detected following device implantation was high, 
and subsequent modification of therapy was common. ICD-de-
livered therapy (ATP and defibrillation) occurred in over a 
quarter of the CIED population, highlighting the increased inci-
dence of life-threatening arrhythmia in these patients. No signif-
icant differences were seen between types of CIEDs, suggesting 
that electrical changes appear to represent progressive cardiac 
disease in all FD patients. Diagnosis of asymptomatic AF from 
a cardiac device was frequent, and it is possible that this may 
contribute to the increased risk of ischaemic stroke, the second 
highest cause of mortality in FD patients. Although the indi-
cation for ICD implantation in FD was variable, an increasing 
number are inserted outside of guidance for primary prevention. 
Of note, almost a third of patients had a device inserted before a 
diagnosis of FD was made.
Arrhythmia is a common cause of morbidity and mortality in 
FD, yet there is no consensus evidence to guide treatment in 
FD patients, and the frequency of VT and VF reported in the 
literature varies widely.8–11 Previous studies have reported very 
low levels of clinically significant arrhythmia identified on device 
follow-up with a ventricular arrhythmia incidence of 5.2% over 
4 years9 and atrioventricular conduction disease of 3.8% over 
2.8 years.24 In our multicentre population, however, the burden 
of ventricular arrhythmia was much higher, with 28% needing 
device therapy over a 4-year follow-up period. Although the 
precise mechanisms of arrhythmia are not fully understood, 
certain structural changes may predispose to ventricular 
arrhythmia and sudden cardiac death, including LVH, ventric-
ular dysfunction and extensive fibrosis with myocardial scar-
ring.25 The evidence of an underlying inflammatory component 
leading to scar may be a potential explanation for any increase 
in arrhythmic risk in FD patients with LGE on CMR, but further 
research is needed.26
Ischaemic stroke is a common and serious clinical finding in 
early and advanced FD, with vascular endothelial sphingolipid 
accumulation thought to play a predominant role in its aeti-
ology.27 Our study has shown that the rate of asymptomatic 
paroxysmal AF in those with advanced FD cardiomyopathy is 
high, suggesting that thromboembolic disease may have a more 
significant role in the aetiology of ischaemic stroke. In our 
control cohort, the rate of Holter monitoring in clinical prac-
tice was low, since monitoring was not a part of the Fabry400 
protocol, suggesting that a greater burden of AF may be detected 
with more detailed surveillance. There is currently no FD-spe-
cific guidance for choice of anticoagulant therapy, and the use of 
the CHA2DS2-VASc scoring system is not recommended in FD 
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Key messages
What is already known on this subject?
 ► Cardiac involvement in Fabry disease is characterised by 
progressive left ventricular hypertrophy, myocardial fibrosis 
and arrhythmia. The incidence of atrial and ventricular 
arrhythmia reported in the literature is variable. Although 
some clinical and imaging parameters have been described 
as markers of arrhythmia, no definitive criteria exist to guide 
device implantation.
What might this study add?
 ► This is the first multicentre study evaluating cardiac device 
implantation practice, arrhythmia burden and device usage 
in Fabry disease. This study demonstrates that indications 
for implantable cardioverter-defibrillator (ICD) implantation 
are variable, and devices are often inserted for primary 
prevention outside of current guidance. The occurrence of 
asymptomatic AF and ventricular arrhythmia requiring ICD 
therapy is high in those with a cardiac device, demonstrating 
an increased arrhythmic risk in those with advanced cardiac 
disease.
how might this impact on clinical practice?
 ► Asymptomatic atrial fibrillation needing anticoagulation and 
ventricular arrhythmia requiring ICD therapy were as common 
as that observed in hypertrophic cardiomyopathy, supporting 
the need for Fabry-specific guidance for medical therapy and 
device implantation.
to guide its initiation.28 29 Given the high incidence and risk of 
stroke in FD, current literature suggests lifelong anticoagulation 
in those with AF.28
Limited data have identified the following potential arrhythmic 
risk factors in FD: LVH, the presence of LGE on CMR, left atrial 
dilatation, a QRS duration greater than 120 ms, previously docu-
mented NSVT and an elevated MSSI above 20.13 Additionally, 
ECG abnormalities, including a prolonged PR interval and QRS 
duration, have been identified as independent predictors of 
pacemaker implantation in FD.14 These factors are common in 
FD patients who have a cardiac device but are also common in a 
large proportion of FD patients without a cardiac device.30 Male 
patients tend to have progressive disease with extensive cardiac 
involvement, and in combination with advancing age, these 
factors are thought to increase risk of ventricular arrhythmia.13 
Further prospective research is needed to clarify risk factors 
on which recommendations for device implantation could be 
based. It is of great concern that almost a third of devices were 
implanted before a diagnosis of FD was confirmed, demon-
strating that delay in diagnosing FD remains an issue in real-
world practice.
The limitations of this study include the possibility that the 
burden of arrhythmia could be underestimated. Specific arrhyth-
mias, such as slow VT not within the device detection range, 
may have been overlooked. Additionally, there may have been 
inappropriate identification of arrhythmia by the device, such as 
AF or artefact mistaken for VT, and consequent mislabeling of a 
rhythm disturbance. To minimise this, in cases where diagnosis 
of arrhythmia was unclear from the device interrogation report, 
all ECG traces were reviewed. Furthermore, a large proportion 
of Holter monitors were performed within local hospitals and 
data were not fully available in specialist centres. Consequently, 
it was not feasible to exclude arrhythmic events in the entire 
FD-control cohort, and definitive comparisons cannot be made 
of arrhythmic burden or presence of risk factors between the 
control and CIED groups. Further prospective studies are needed 
to definitively characterise arrhythmic risk and guide treatment 
based on their risk stratification.
ConClusIon
Cardiac device implantation is variable and does not always 
follow current guidance. This is true particularly for ICDs 
with many devices now inserted based on clinical suspicion 
of arrhythmia. Arrhythmias are common in Fabry patients 
following CIED implantation, with high rates of asymptomatic 
AF requiring anticoagulation and ventricular arrhythmia needing 
ICD device treatment. These are as high as those seen in HCM, 
supporting the need for prospective studies to inform Fabry-spe-
cific guidance for cardiac device implantation.
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